

Title (en)  
COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES EXHIBITING PROTEIN MISASSEMBLY AND AGGREGATION

Title (de)  
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON KRANKHEITEN MIT PROTEIN-FEHLANORDNUNG UND AGGREGATION

Title (fr)  
COMPOSITIONS ET PROCEDES DE TRAITEMENT DE MALADIES PRESENTANT UN DEFAUT D'ASSEMBLAGE ET UNE AGREGATION DE PROTEINES

Publication  
**EP 1575510 A4 20071226 (EN)**

Application  
**EP 03785053 A 20030807**

Priority  

- US 0324868 W 20030807
- US 40219802 P 20020807

Abstract (en)  
[origin: WO2004014306A2] Compounds, compositions, and pharmaceutical compositions comprising oligonucleotides capable of disrupting protein aggregations that are characteristic of disorders of protein assembly are described, as are in vitro and in vivo methods for identifying usch oligonucleotides, and methods for treating such disorders by administration of such compositions.

IPC 1-7  
**A61K 48/00**; **C12Q 1/68**

IPC 8 full level  
**A61K 6/00** (2006.01); **A61K 31/7088** (2006.01); **A61K 48/00** (2006.01); **A61P 25/28** (2006.01); **C12N 15/11** (2006.01); **C12Q 1/04** (2006.01); **C12Q 1/68** (2006.01); **G01N 33/68** (2006.01)

IPC 8 main group level  
**A61K** (2006.01)

CPC (source: EP)  
**A61P 3/10** (2017.12); **A61P 9/04** (2017.12); **A61P 9/10** (2017.12); **A61P 13/12** (2017.12); **A61P 21/02** (2017.12); **A61P 25/00** (2017.12); **A61P 25/16** (2017.12); **A61P 25/28** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **G01N 33/6896** (2013.01)

Citation (search report)  

- [PX] WO 03013437 A2 20030220 - UNIV DELAWARE [US]
- [PX] WO 02065136 A2 20020822 - UNIV CHICAGO [US], et al
- [Y] WO 0123412 A2 20010405 - MASSACHUSETTS INST TECHNOLOGY [US], et al
- [A] WO 0073501 A2 20001207 - LASMEZAS CORINNE IDA [FR], et al
- [A] WO 02054083 A2 20020711 - ORTHO MCNEIL PHARM INC [US]
- [A] WO 9929891 A1 19990617 - ARCH DEV CORP [US], et al
- [A] WO 9906545 A2 19990211 - MAX PLANCK GESELLSCHAFT [DE], et al
- [Y] PROSKE DANIELA ET AL: "Prion-protein-specific aptamer reduces PrPSc formation.", CHEMBIOCHEM : A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY. 2 AUG 2002, vol. 3, no. 8, 2 August 2002 (2002-08-02), pages 717 - 725, XP002401585, ISSN: 1439-4227
- [A] CORDEIRO Y ET AL: "DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BIRMINGHAM, US, vol. 276, no. 52, 28 December 2001 (2001-12-28), pages 49400 - 49409, XP002196440, ISSN: 0021-9258
- [A] KHOSHMAN ALI ET AL: "Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 2, 22 January 2002 (2002-01-22), pages 1002 - 1007, XP002401586, ISSN: 0027-8424
- [A] LECERF J-M ET AL: "Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 8, 10 April 2001 (2001-04-10), pages 4764 - 4769, XP002323805, ISSN: 0027-8424
- See references of WO 2004014306A2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

Designated extension state (EPC)  
AL LT LV MK

DOCDB simple family (publication)  
**WO 2004014306 A2 20040219**; **WO 2004014306 A3 20060518**; AU 2003259073 A1 20040225; CA 2494908 A1 20040219; CN 101123993 A 20080213; EP 1575510 A2 20050921; EP 1575510 A4 20071226; IL 166706 A0 20060115; JP 2006509726 A 20060323; KR 20050053607 A 20050608; NO 20051159 L 20050426; NZ 538145 A 20080530

DOCDB simple family (application)  
**US 0324868 W 20030807**; AU 2003259073 A 20030807; CA 2494908 A 20030807; CN 03823896 A 20030807; EP 03785053 A 20030807; IL 16670605 A 20050206; JP 2004527888 A 20030807; KR 20057002251 A 20050207; NO 20051159 A 20050304; NZ 53814503 A 20030807